ReviewBiosensors2026
Conducting Polymer-Nanomaterial Hybrids for Cancer Diagnostics.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cancer continues to pose a major global burden because of the high incidence and mortality, underscoring the urgent need for innovative and highly sensitive diagnostic technologies. Conducting polymer-nanomaterial (CP-NM) hybrid biosensors have become promising platforms for cancer biomarker detection, integrating the redox-active and biocompatible nature of conducting polymers such as polyaniline (PANI), polypyrrole (PPy), and poly(3,4-ethylenedioxythiophene) (PEDOT) with the high surface area and charge transport properties of nanomaterials, including metallic nanoparticles, metal oxides, carbon-based nanostructures, and two-dimensional materials. The synergistic interfaces in these hybrids enable efficient electron transfer, signal amplification, and stable biomolecular immobilization, facilitating ultrasensitive and multiplexed detection of proteins, nucleic acids, and metabolites associated with tumor progression. This review highlights recent advances in CP-NM hybrid biosensors for cancer diagnostics, focusing on material design strategies, sensing mechanisms, and representative applications across electrochemical, optical, and mechanical modalities. Finally, key challenges and future perspectives are discussed, emphasizing the potential of CP-NM hybrid platforms to drive next-generation approaches for early cancer detection, therapeutic monitoring, and personalized healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.